Does the media refer more to PTGX or MRNA?

In the previous week, Moderna had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 40 mentions for Moderna and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 17 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTGX or BNTX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.09 beat BioNTech's score of 0.85 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or PTGX?

In the previous week, Roivant Sciences had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Protagonist Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat Protagonist Therapeutics' score of 1.09 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or INSM?

In the previous week, Insmed had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 4 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.32 beat Protagonist Therapeutics' score of 1.09 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or VTRS?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.09 beat Viatris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Protagonist Therapeutics (PTGX) Competitors

$118.96 +3.93 (+3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$118.81 -0.15 (-0.13%)

As of 07:03 PM Eastern

Compare

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Protagonist Therapeutics compare to Moderna?

Protagonist Therapeutics (NASDAQ:PTGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 40 mentions for Moderna and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	10 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna has a net margin of -143.55% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Moderna	-143.55%	-26.64%	-19.32%

Protagonist Therapeutics currently has a consensus target price of $115.21, indicating a potential downside of 3.15%. Moderna has a consensus target price of $36.60, indicating a potential downside of 40.00%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Protagonist Therapeutics has higher earnings, but lower revenue than Moderna. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
Moderna	$2.20B	10.98	-$2.82B	-$8.15	N/A

Summary

Protagonist Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to BioNTech?

Protagonist Therapeutics (NASDAQ:PTGX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Protagonist Therapeutics has higher earnings, but lower revenue than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
BioNTech	$2.81B	8.17	-$1.29B	-$5.88	N/A

In the previous week, Protagonist Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.09 beat BioNTech's score of 0.85 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
BioNTech	-44.39%	-5.30%	-4.62%

Protagonist Therapeutics presently has a consensus target price of $115.21, suggesting a potential downside of 3.15%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 42.97%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Protagonist Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Protagonist Therapeutics beats BioNTech on 8 of the 15 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Roivant Sciences had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Protagonist Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat Protagonist Therapeutics' score of 1.09 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential upside of 4.29%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential downside of 3.15%. Given Roivant Sciences' higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,804.80	-$299.77M	-$0.60	N/A
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -3,629.19%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Summary

Protagonist Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Protagonist Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

In the previous week, Insmed had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 4 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.32 beat Protagonist Therapeutics' score of 1.09 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Insmed has a net margin of -144.44% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Insmed	-144.44%	-130.11%	-51.57%

Protagonist Therapeutics presently has a consensus price target of $115.21, indicating a potential downside of 3.15%. Insmed has a consensus price target of $211.86, indicating a potential upside of 107.40%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
Insmed	$606.42M	36.51	-$1.28B	-$5.75	N/A

Summary

Protagonist Therapeutics and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Viatris?

Protagonist Therapeutics (NASDAQ:PTGX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Protagonist Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Viatris. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
Viatris	$14.56B	1.26	-$3.51B	-$0.26	N/A

Viatris has a net margin of -2.04% compared to Protagonist Therapeutics' net margin of -154.88%. Viatris' return on equity of 19.04% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Viatris	-2.04%	19.04%	7.62%

Protagonist Therapeutics currently has a consensus price target of $115.21, indicating a potential downside of 3.15%. Viatris has a consensus price target of $17.50, indicating a potential upside of 11.11%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.09 beat Viatris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.65B	$3.45B	$6.46B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-65.72	20.09	24.71	24.00
Price / Sales	103.30	188.30	492.47	90.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	12.10	8.28	10.82	6.53
Net Income	-$130.15M	$23.85M	$3.56B	$336.99M
7 Day Performance	7.52%	5.21%	1.67%	-0.22%
1 Month Performance	19.93%	2.19%	0.43%	0.77%
1 Year Performance	122.94%	60.99%	32.84%	31.57%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.2739 of 5 stars	$118.96 +3.4%	$115.21 -3.1%	+115.7%	$7.65B	$74.06M	N/A	120	Positive News
MRNA Moderna	1.2423 of 5 stars	$63.96 flat	$36.60 -42.8%	+129.2%	$25.38B	$1.94B	N/A	4,700	High Trading Volume
BNTX BioNTech	4.5365 of 5 stars	$90.89 flat	$129.56 +42.5%	-15.3%	$22.98B	$3.25B	N/A	7,807
ROIV Roivant Sciences	1.8735 of 5 stars	$31.43 flat	$33.59 +6.9%	+172.9%	$22.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.488 of 5 stars	$95.70 -0.1%	$211.86 +121.4%	-4.0%	$20.76B	$606.42M	N/A	1,664	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Protagonist Therapeutics compare to Moderna?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Protagonist Therapeutics compare to Moderna?

Do institutionals & insiders believe in PTGX or MRNA?

Which has more volatility and risk, PTGX or MRNA?

Does the media refer more to PTGX or MRNA?

Is PTGX or MRNA more profitable?

Do analysts recommend PTGX or MRNA?

Which has preferable valuation and earnings, PTGX or MRNA?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Which has better earnings & valuation, PTGX or BNTX?

Does the media refer more to PTGX or BNTX?

Do insiders and institutionals hold more shares of PTGX or BNTX?

Is PTGX or BNTX more profitable?

Do analysts rate PTGX or BNTX?

Which has more risk & volatility, PTGX or BNTX?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Does the media refer more to ROIV or PTGX?

Do analysts recommend ROIV or PTGX?

Which has more risk & volatility, ROIV or PTGX?

Do insiders & institutionals believe in ROIV or PTGX?

Which has better earnings and valuation, ROIV or PTGX?

Is ROIV or PTGX more profitable?

Summary

How does Protagonist Therapeutics compare to Insmed?

Which has more risk and volatility, PTGX or INSM?

Does the media favor PTGX or INSM?

Do insiders and institutionals believe in PTGX or INSM?

Is PTGX or INSM more profitable?

Do analysts recommend PTGX or INSM?

Which has better earnings and valuation, PTGX or INSM?

Summary

How does Protagonist Therapeutics compare to Viatris?

Which has more risk & volatility, PTGX or VTRS?

Which has stronger earnings and valuation, PTGX or VTRS?

Is PTGX or VTRS more profitable?

Do analysts prefer PTGX or VTRS?

Does the media favor PTGX or VTRS?

Do insiders & institutionals hold more shares of PTGX or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools